Currently, the biomarkers that have been identified for potential targeted therapy treatments for lung cancer are: EGFR, ALK, KRAS, MET, HER2, ROS1, BRAF, RET, NTRK1, PID3CA, MED1, VEGFR2, HER3, and IGF-1R. Of those, so far only EGFR, ALK+, and ROS1 have treatments approved by the FDA. However, there are many more treatments that are in clinical trials.
In this section of the Hope With Answers℠ series, learn more about the ALK+ biomarker and the most current information available regarding approved treatments.
Hope With Answers℠ Video Series: ALK Positive Biomarker
Patient and Advocate Shelly Engfer-Triebenbach speaks with lung cancer researcher Dr. Alice Shaw from Massachusetts General Hospital about ALK+ lung cancer.